TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33538700

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound before laparoscopic cholecystectomy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intraoperative cholangiography during laparoscopic cholecystectomy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound and endoscopic retrograde cholangiography on demand
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intraoperative cholangiography
Number of subjects: 106

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography on demand
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 106

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound, intraoperative cholangiography, and endoscopic retrograde cholangiography
Number of subjects: 106
Study: 33538699

Group type: EXPERIMENTAL
Intervention: Mobile health and self-management app (8-week program including Lung Attack Action Plan, education, medication overview, video consultation, and questionnaires)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mobile health and self-management app
Number of subjects: 39
Study: 33538761

Group type: EXPERIMENTAL
Intervention: Povidone Iodine Mouthwash, Gargle, and Nasal Spray
Number of subjects: 0
Study: 33538797

Group type: EXPERIMENTAL
Intervention: Venetoclax plus R-CHOP
Number of subjects: 206

Group type: COMPARATOR
Intervention: R-CHOP (control group from GOYA/BO21005 study)
Number of subjects: 206
Study: 33538996

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/formoterol fumarate (BDP/FF) NEXThaler
Number of subjects: 43
Study: 33539138

Group type: EXPERIMENTAL
Intervention: Web-based symptom management program (My MS toolkit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33539145

Group type: EXPERIMENTAL
Intervention: self/group-therapist alliance dimension
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: other-therapist alliance dimension
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: within-system alliance dimension
Number of subjects: 165
Study: 33539144

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Number of subjects: 54
Study: 33539543

Group type: EXPERIMENTAL
Intervention: Freeze all strategy
Number of subjects: 4712

Group type: COMPARATOR
Intervention: Conventional IVF/ICSI strategy
Number of subjects: 4712
Study: 33539561

Group type: EXPERIMENTAL
Intervention: Non-exergames
Number of subjects: 468

Group type: COMPARATOR
Intervention: Cognitive remediation
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Exergames
Number of subjects: 468
Study: 33539714

Group type: EXPERIMENTAL
Intervention: Trexo Home robotic gait trainer
Number of subjects: 1
Study: 33539743

Group type: EXPERIMENTAL
Intervention: 55 Gy in 20 fractions
Number of subjects: 782

Group type: COMPARATOR
Intervention: 64 Gy in 32 fractions
Number of subjects: 782
Study: 33539762

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 1456
Study: 33539837

Group type: EXPERIMENTAL
Intervention: Slow Vital Capacity (SVC)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Forced Vital Capacity (FVC)
Number of subjects: 854
Study: 33540481

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latency reversal agents
Number of subjects: 0
Study: 33540485

Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 150 IU/kg daily for 6 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: DalcA (intravenous 75 IU/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 75 IU/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 150 IU/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: BeneFIX (intravenous 75 IU/kg)
Number of subjects: 11
Study: 33541097

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention
Number of subjects: 300
Study: 33541106

Group type: EXPERIMENTAL
Intervention: Clinical risk
Number of subjects: 13172

Group type: COMPARATOR
Intervention: Procedural risk
Number of subjects: 13172

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 13172
Study: 33541235

Group type: EXPERIMENTAL
Intervention: Home nebulizer inhaled corticosteroid (ICS) therapy
Number of subjects: 510
Study: 33541279

Group type: EXPERIMENTAL
Intervention: Troponin T (TnT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Abdominal aortic calcification score (AAC)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Maximal ergometry workload (in Watts)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: AAC and TnT
Number of subjects: 174
Study: 33541340

Group type: EXPERIMENTAL
Intervention: HBB Prompt mobile application
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group without the app
Number of subjects: 13
Study: 33541356

Group type: EXPERIMENTAL
Intervention: Persistently controlled patients (134 patients, 16.8%)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Persistently uncontrolled patients (248 patients, 31.1%)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Patients who changed control status (416 patients, 52.1%)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Triple inhaled therapy
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Bronchodilators for monotherapy
Number of subjects: 798
Study: 33541436

Group type: EXPERIMENTAL
Intervention: Truncal ablation, simultaneous iliac interrogation with intravascular ultrasound and stenting of significant (> 50%) iliac vein lesions plus compression therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Truncal ablation and compression therapy
Number of subjects: 60
Study: 33541439

Group type: EXPERIMENTAL
Intervention: High-Performance Leader group (HPL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-Performance Leader group (LPL)
Number of subjects: 40
Study: 33541735

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temsirolimus
Number of subjects: 0
Study: 33542052

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin (10-35 mg·kg)
Number of subjects: 0
Study: 33542056

Group type: EXPERIMENTAL
Intervention: 40 mg·kg of rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg·kg of rifampicin
Number of subjects: 0
Study: 33542073

Group type: EXPERIMENTAL
Intervention: LTX-315
Number of subjects: 39
Study: 33542131

Group type: EXPERIMENTAL
Intervention: Responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 therapy
Number of subjects: 15
Study: 33542624

Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide/glycopyrrolate/formoterol fumarate) 320/18/9.6 µg
Number of subjects: 1896

Group type: COMPARATOR
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate) 18/9.6 µg
Number of subjects: 1896
Study: 33542653

Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution (OS) single dose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tapentadol intravenous infusion (IV) single dose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tapentadol oral solution (OS) multiple doses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo in multiple doses
Number of subjects: 72
Study: 33542696

Group type: EXPERIMENTAL
Intervention: Dysfunctional coping strategies (alcohol use, avoidance, distraction)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: PTSS
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Prevalence of suspected PTSD
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Years on job
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Work-related trauma
Number of subjects: 1002
Study: 33543056

Group type: EXPERIMENTAL
Intervention: High-frequency pulse (HFP) TLNS plus PT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-frequency pulse (LFP) TLNS plus PT
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment after 14 weeks)
Number of subjects: 44
Study: 33543425

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa (ERT)
Number of subjects: 68
Study: 33543444

Group type: EXPERIMENTAL
Intervention: Transformed migraine patients with subjective cognitive impairment (SCI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transformed migraine patients with SCI
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polysomnography parameters in TM patients with SCI
Number of subjects: 120
Study: 33544087

Group type: EXPERIMENTAL
Intervention: Routine diagnostic care, 3 Tesla cardiovascular MRI, transthoracic echocardiography, 20-min high-resolution electrocardiogram, extensive biobanking
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine diagnostic care
Number of subjects: 300
Study: 33544207

Group type: EXPERIMENTAL
Intervention: WCRF dietary recommendations adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carnivore dietary pattern
Number of subjects: 0

Group type: COMPARATOR
Intervention: DHD15-index, Western pattern, Prudent pattern
Number of subjects: 0
Study: 33544279

Group type: EXPERIMENTAL
Intervention: PIPAC-OX (Oxaliplatin)
Number of subjects: 20
Study: 33544318

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300-mg maintenance therapy every 8, 6, or 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300-mg maintenance therapy every 8 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300-mg maintenance therapy
Number of subjects: 11
Study: 33544407

Group type: EXPERIMENTAL
Intervention: FTD/TPI plus nivolumab
Number of subjects: 18
Study: 33544717

Group type: EXPERIMENTAL
Intervention: Universal HIV testing and ART coverage
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Mobile men (≥1 month of prior year living outside community)
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: HIV tested at home vs. health fair
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Women aged ≤24 years
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Mobile women
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Women with a prior HIV test
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Women who reported alcohol use
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Suspected infection source for women
Number of subjects: 117114

Group type: EXPERIMENTAL
Intervention: Suspected infection source for men
Number of subjects: 117114
Study: 33544889

Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) with the Sonata system
Number of subjects: 197
Study: 33544969

Group type: EXPERIMENTAL
Intervention: Physician Global Assessment (PhGA) scored on a scale of 0-10 by 3 physicians
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Physician Global Assessment (PhGA)
Number of subjects: 78
Study: 33545083

Group type: EXPERIMENTAL
Intervention: Rescue therapy (including primary induction) or colectomy during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Time to rescue therapy during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Use of rescue and primary induction therapies with biologicals, ciclosporin, or tofacitinib during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Ambulatory (outpatient) intravenous steroids during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Use of thiopurines during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Use of 5-aminosalicylic acids during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Colectomy rates during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery during the COVID-19 pandemic period
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Incidence of SARS-CoV-2 during hospital treatment
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Re-testing for SARS-CoV-2 during 3-month follow-up
Number of subjects: 782
Study: 33545389

Group type: EXPERIMENTAL
Intervention: ALK inhibitors (ALKi)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: FISH analysis for ALK rearrangement
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Baseline levels or dynamic change of CTCs
Number of subjects: 203
Study: 33545397

Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 0
Study: 33545440

Group type: EXPERIMENTAL
Intervention: Therapeutic rest using intramuscular morphine sulfate and promethazine
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Therapeutic rest
Number of subjects: 82
Study: 33545667

Group type: EXPERIMENTAL
Intervention: SCT-based intervention (12-week duration)
Number of subjects: 13
Study: 33545688

Group type: EXPERIMENTAL
Intervention: Durvalumab following cCRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: cCRT alone
Number of subjects: 0
Study: 33546029

Group type: EXPERIMENTAL
Intervention: Lower lymphocyte to monocyte ratio (LMR)
Number of subjects: 4666
Study: 33546373

Group type: EXPERIMENTAL
Intervention: Dating violence victimization among girls
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Dating violence victimization among boys
Number of subjects: 1555
Study: 33546494

Group type: EXPERIMENTAL
Intervention: Methadone (MTD)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Buprenorphine (BHD)
Number of subjects: 257
Study: 33546607

Group type: EXPERIMENTAL
Intervention: Mixed-effects models
Number of subjects: 3603

Group type: COMPARATOR
Intervention: Simple imputation based on the nearest measure
Number of subjects: 3603

Group type: COMPARATOR
Intervention: Simple arithmetic imputation based on the nearest two measures
Number of subjects: 3603

Group type: COMPARATOR
Intervention: Marginal models with generalized estimating equations
Number of subjects: 3603
Study: 33546615

Group type: EXPERIMENTAL
Intervention: Complex chronic patients (CCPs)
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: HAS-BLED score ≥3
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 3594

Group type: EXPERIMENTAL
Intervention: Incidence density of ICH in CCP subgroup
Number of subjects: 3594
Study: 33546620

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Grip strength (Jamar®)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Dual-task cost (DTC)
Number of subjects: 567
Study: 33546641

Group type: EXPERIMENTAL
Intervention: Brief individual oral and visual information on vitamin D given by doctors at baseline and after four and ten months
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Focus-group interviews conducted after two years
Number of subjects: 91
Study: 33546642

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiosurgery (HSRS)
Number of subjects: 70
Study: 33546709

Group type: EXPERIMENTAL
Intervention: CONEMO intervention combining a smartphone app with support from non-specialized professionals
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group supervision meetings
Number of subjects: 65
Study: 33546716

Group type: EXPERIMENTAL
Intervention: Self Help+ intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone and video data collection methods
Number of subjects: 0
Study: 33546731

Group type: EXPERIMENTAL
Intervention: Cellular markers of inflammation (WBC, neutrophils, NLR)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Change in cellular markers of inflammation from T1 to T2
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Frailty score pre-chemotherapy (T1) vs post-chemotherapy (T2)
Number of subjects: 581
Study: 33546927

Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Low-risk patients
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 970
Study: 33547157

Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention
Number of subjects: 18
Study: 33547229

Group type: EXPERIMENTAL
Intervention: RAID questionnaire (NRS for pain)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: RAID questionnaire (NRS for sleep disturbance)
Number of subjects: 671
Study: 33547528

Group type: EXPERIMENTAL
Intervention: P-PENK > 84.8 pmol/mL at baseline
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: P-NGAL > 104 ng/mL at baseline
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: P-PENK and P-NGAL levels at baseline
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: P-PENK and P-NGAL levels at 24 h
Number of subjects: 154
Study: 33547559

Group type: EXPERIMENTAL
Intervention: Intravenous bolus doses of morphine via patient-controlled analgesia
Number of subjects: 25
Study: 33547694

Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy (EAT)
Number of subjects: 19
Study: 33547966

Group type: EXPERIMENTAL
Intervention: Ocular prosthesis rehabilitation (using a 72-item questionnaire, reduced to a 20-item questionnaire)
Number of subjects: 100
Study: 33548234

Group type: EXPERIMENTAL
Intervention: Gastroparesis
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia
Number of subjects: 944

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 944

Group type: COMPARATOR
Intervention: Gastric-emptying results
Number of subjects: 944
Study: 33548339

Group type: EXPERIMENTAL
Intervention: RT (55.8 Gy) for R1 ≤5 cm tumor (arm B)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RT (55.8 Gy)/CT for R0/R1 >5 cm tumor (arm C)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0 <5 mm margins/R1 or 19.8 Gy for R2/unresected tumors (arm D)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Overall local control (LC) after RT
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Neoadjuvant CT/RT
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 5-year event-free survival
Number of subjects: 193
Study: 33548397

Group type: EXPERIMENTAL
Intervention: Brodalumab (IL-17RA antagonist)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Untreated HS patients
Number of subjects: 2
Study: 33548468

Group type: EXPERIMENTAL
Intervention: Reslizumab (3 mg/kg)
Number of subjects: 10
Study: 33548471

Group type: EXPERIMENTAL
Intervention: Inhaled triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33548517

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 4

Group type: COMPARATOR
Intervention: omalizumab
Number of subjects: 4
Study: 33548750

Group type: EXPERIMENTAL
Intervention: Touch massage (TM) delivered by trained members of care team, at least 4 sessions over two weeks.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Foot massage device, intervention of the same duration as TM.
Number of subjects: 78
Study: 33549070

Group type: EXPERIMENTAL
Intervention: Infant Motor Profile (IMP) Total Score
Number of subjects: 86
Study: 33549128

Group type: EXPERIMENTAL
Intervention: ERITA (Emotion Regulation Individual Therapy for Adolescents) as an add-on to treatment as usual
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 30
Study: 33549152

Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF) guided intervention
Number of subjects: 261
Study: 33549436

Group type: EXPERIMENTAL
Intervention: Higher dietary fiber intake
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Higher fat intake
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Nut consumption
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Dietary quality index (DQI) and DQI for Mediterranean diet
Number of subjects: 212
Study: 33549447

Group type: EXPERIMENTAL
Intervention: Urinary potassium excretion in black individuals
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Sodium/potassium (Na/K) ratio in black individuals
Number of subjects: 423

Group type: COMPARATOR
Intervention: Elevated 24 h diastolic BP in both groups
Number of subjects: 423
Study: 33549559

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPX) parameters
Number of subjects: 400
Study: 33549569

Group type: EXPERIMENTAL
Intervention: Olfactory cleft (OC) biomarkers
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Psychophysical olfactory testing, Questionnaire of Olfactory Dysfunction (QOD-NS), and bilateral OC endoscopy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (70 subjects)
Number of subjects: 198
Study: 33549599

Group type: EXPERIMENTAL
Intervention: Preterm with BPD
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Preterm without BPD
Number of subjects: 86

Group type: COMPARATOR
Intervention: Full term
Number of subjects: 86
Study: 33549601

Group type: EXPERIMENTAL
Intervention: Ultra-small cysts identified by high-resolution CT scan
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard chest CT imaging
Number of subjects: 103
Study: 33549871

Group type: EXPERIMENTAL
Intervention: Tethered capsule endomicroscopy (TCE)
Number of subjects: 147
Study: 33550173

Group type: EXPERIMENTAL
Intervention: Ticagrelor administration
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study: 33550225

Group type: EXPERIMENTAL
Intervention: Multimorbidity measured by disease count
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimorbidity measured by Charlson's Comorbidity Index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuity of care measured by the Usual Provider Continuity Index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression analysis
Number of subjects: 0
Study: 33550236

Group type: EXPERIMENTAL
Intervention: Management measures for jaundice before admission
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Follow-up outcomes
Number of subjects: 2000
Study: 33550254

Group type: COMPARATOR
Intervention: MedDiet
Number of subjects: 108

Group type: COMPARATOR
Intervention: MedDiet+PA
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control
Number of subjects: 108
Study: 33550302

Group type: EXPERIMENTAL
Intervention: Bronchoscopic lung volume reduction (BLVR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Before BLVR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: After BLVR
Number of subjects: 20